NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
11/20/2025
Back to search
Official data from USPTO
CELL THERAPY 360
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CELL THERAPY 360
ST13
US500000088347099Class
5, 9, 36, 42, 44, 45
Filing
88347099
Registration
5889482
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
12/09/2025
Trademark type
Word
Nice classes
5, 9, 36, 42, 44, 45
Filing date
03/19/2019
Registration date
10/22/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/20/2025
Last transaction
12/09/2025
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Summit, NJ
Examiner
OESTREICHER,SALIMA PARMAR
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
C. C. (pessoa física)
Representatives
Marilyn F. Kelly Bristol-Myers Squibb Company
Technical classification
Nice Classes
Class 5Class 9Class 36Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationspreparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapyincluding T Cell therapy
Class 9
Downloadable computer software enabling patients to manage and access data relating to the treatment of cancer and immunological disorders; downloadable computer application software for use on mobile phones and mobile electronic devices for use in connection with providing medical information in the field of cancer and immunological disorders; downloadable electronic publicationsnewsletters and articles featuring medical information in the field of cancer and immunological disorders; downloadable videos featuring medical information in the field of cancer and immunological disorders; downloadable computer software for application and database integration
Class 36
Financial administration of patient reimbursement programs; financial administration of medication reimbursement programs and services
Class 42
Software as a Service (SaaS) services featuring software that allows patients to manage and access data relating to the treatment of cancer and immunological disorders; application service provider (ASP) featuring software for medical affair management and information exchange; providing a website featuring non-downloadable software for medical affair management and information exchange; providing an on-line computer database featuring medical and scientific research information in the field of cancer and immunological disorders that allows for input and collection of scientific and research data and information; medical and scientific research liaison servicesconsulting in the field of scientific research pertaining to clinical trials in the fields of health caremedicinepharmacology and biotechnology; scientific research consultation pertaining to clinical trials; providing medical and scientific research information in the field of clinical trials
Class 44
Providing medical information; providing health information in the field of oncology and immunological disorders; providing a web site featuring medical information; providing a web site featuring health information in the field of oncology and immunological disorders; providing medical informationconsultancy and advisory services; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals
Class 45
Providing patient advocate services in the field of the treatment of diseases and disorders
Publications
History of USPTO decisions and trademark events.
36 publications found
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
11/20/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/20/2025
E815
TEAS SECTION 8 & 15 RECEIVED
08/04/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/22/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/09/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/09/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
12/09/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/09/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/09/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/09/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
10/22/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/06/2019
PUBO
PUBLISHED FOR OPPOSITION
08/06/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/17/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/28/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
06/28/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/28/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
06/28/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/28/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/24/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/21/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/01/2019
GNSL
LETTER OF SUSPENSION E-MAILED
05/01/2019
CNSL
SUSPENSION LETTER WRITTEN
05/01/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
05/01/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/01/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
05/01/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/01/2019
DOCK
ASSIGNED TO EXAMINER
04/28/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/06/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
03/30/2019
ALIE
ASSIGNED TO LIE
03/28/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/22/2019
NWAP
NEW APPLICATION ENTERED
03/22/2019
Continuous trademark protection
Get notified about every new filing that threatens CELL THERAPY 360 or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.